99% Apixaban CAS 503612-47-3

Inkcazelo emfutshane:

Igama lomchiza:Apixaban
Elinye igama:1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine -3-carboxaMide;1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,
I-5-dihydropyrazolo [3,4-c] pyridine-3-carboxaMide
Inombolo yeCAS:503612-47-3
Ubunyulu:99% min
Ifomula:I-C25H25N5O4
Ubunzima beMolekyuli:459.50
Iinkcazelo ngeMichiza:I-Apixaban i-crystalline powder emhlophe.Luhlobo olutsha lwe-oral Xa factor inhibitor, kwaye igama layo lentengiso ngu-Eliquis.I-Apixaban isetyenziselwa ukunyanga izigulane ezikhulileyo ezithatha utyando olukhethiweyo lwe-hip okanye idolo ukukhusela i-venous thromboembolism (VTE).

Thumela i-imeyile kuthi

Iinkcukacha zeMveliso

Iithegi zeMveliso

Inkcazo

INTO	UMGANGATHO
Imbonakalo	Okumhlophe ukuya kumhlophe okuqinileyo
Ubunyulu	≥ 99%

Isicelo

I-Apixaban luhlobo olutsha lwe-anticoagulant yomlomo, uhlobo olutsha lwe-oral factor Xa inhibitor, esetyenziselwa ukukhusela nokuphatha amahlule egazi.
I-Apixaban yinto entsha yomlomo xa inhibitor ephuhliswe ngokudibeneyo yiBristol-Myers Squibb kunye nePfizer.Ngokuthintela i-coagulation factor Xa, i-apixaban ikhusela ukuveliswa kwe-thrombin kunye ne-thrombosis.

Ngo-Aprili 26, i-2007, i-Bristol-Myers Squibb kunye ne-Pfizer babhengeze uphuhliso oludibeneyo lwe-apixaban yomlomo omtsha we-anticoagulant ophethwe nguBristol-Myers Squibb njengenye indlela ephuculweyo ye-warfarin.
NgoMeyi 2011, i-apixaban yaba ngowokuqala ukuvunywa ekukhuselweni kwe-venous thrombosis kwizigulane zabantu abadala ezithatha utyando olukhethiweyo lwe-hip okanye idolo kumazwe angama-27 e-EU, e-Iceland naseNorway.
NgoNovemba 20, i-2012, iKomishoni yaseYurophu yavuma i-ELIQUIS (i-apixaban) yokuthintela ukubethelwa kwesifo kunye ne-systemic embolism kubantu abadala abane-non-valvular atrial fibrillation (NVAF) kunye neengozi enye okanye ngaphezulu.
I-Canadian Food and Drug Administration, eJapan, kunye ne-US Food and Drug Administration emva koko ivunyiwe i-ELIQUIS (i-apixaban) yokukhusela i-stroke kunye ne-systemic embolism kubantu abadala abane-non-valvular atrial fibrillation (NVAF) kunye neengozi enye okanye ngaphezulu.
Ngo-Aprili 12, i-2013, i-ELIQUIS (i-Apixaban), yabhengezwa ngokusemthethweni kwimarike yaseChina.I-Apixaban iyinoveli yomlomo xa inhibitor yokuthintela i-venous thromboembolism (VTE) kwizigulane zabantu abadala ezithatha utyando olukhethiweyo lwe-hip okanye idolo.Ukuqaliswa kwayo kunika inketho entsha ekhuselekileyo nesebenzayo ye-anticoagulation emva kotyando lwamathambo ekusebenzeni kweklinikhi, kwaye izisa iindaba ezilungileyo kwizigulane zaseTshayina ezithatha indawo ekhethiweyo ye-hip / idolo.
Izifundo zeklinikhi ziqinisekisile ukuba xa kuthelekiswa ne-40 mg ye-enoxaparin engaphantsi kwe-enoxaparin kanye ngosuku, i-2.5 mg ye-ELIQUIS (Apixaban) ngomlomo kabini ngosuku iyasebenza kakhulu ekukhuseleni iziganeko ze-venous thromboembolic emva kokuhlinzwa kwe-hip okanye idolo, kwaye ayinyusi ingozi ukopha.